Non-Small Cell Lung Cancer ("NSCLC")

  • Lung cancer is a leading cause of cancer-related mortality around the world and effective treatment remains a significant global unmet need despite advances in therapy.
  • In general, prognosis for lung cancer patients remains poor, with 5-year relative survival less than 14% among males and less than 18% among females in most countries.
  • Non-small cell lung cancer ("NSCLC") is the most common type of lung cancer.
  • NSCLC accounts for 85% of all lung cancer cases in the United States and approximately 90% of lung cancer cases diagnosed in China.
  • Globally, the market for lung cancer treatment may exceed $7 billion by 2019 according to report published by Transparency Market research.
  • Platinum-based chemotherapy remains standard-of-care for non-resectable NSCLC, in addition to radiation for stage III or IV lung cancer. Some patients exhibiting EGFR-mutation may receive tyrosine kinase (TKI) therapy, often following failure of platinum based chemotherapy.
  • Patients with refractory or resistant NSCLC have limited therapeutic options.


Historical clinical trials sponsored by the U.S. National Cancer Institute ("NCI") support the activity of VAL-083 as a potential treatment for NSCLC. VAL-083 is approved for the treatment of lung cancer in China; however, use of VAL-083 in China has been limited by a lack of modern data.

Based on our research, we believe that VAL-083's unique anti-cancer mechanism could make it a valuable drug of choice in the treatment of NSCLC

DelMar's research demonstrates that VAL-083's mechanism is distinct from platinum-based chemotherapy, the current standard of care for NSCLC. VAL-083 retains its high level of anti-cancer activity in NSCLC phenotypes, which are highly resistant to current therapy. The data also suggest that the combination of VAL-083 with either cisplatin or oxaliplatin provides a super-additive (synergistic) effect against NSCLC cell lines, including those resistant to TKI therapy in vitro.

Effect of VAL-083 Effect of DAG

DelMar believes this data suggests the potential of VAL-083 to address the modern unmet medical needs in the treatment of NSCLC, especially where other therapies have failed or are predicted to give sub-optimal outcomes.

In addition, VAL-083 readily crosses the blood brain barrier, suggesting that it may be possible for VAL-083 to treat patients whose lung cancer has metastasized to the brain.

DelMar plans to initiate a clinical trial in NSCLC in collaboration with Guangxi Wuzhou Pharmaceutical Group Co. Ltd. (Guangxi Wuzhou Pharma). Under the terms of the collaboration Guangxi Wuzhou Pharma will fund the planned study and DelMar will be responsible for protocol development and conduct of the trial.

  1. Youlden et al. The International Epidemiology of Lung Cancer: geographical distribution and secular trends, J Thorac Oncol. 2008 Aug;3(8):819-31
  2. Molona et al. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. as: Mayo Clin Proc. 2008 May; 83(5): 584-594